Factor V Leiden and pulmonary embolism in a young woman taking an oral contraceptive

American Journal of Forensic Medicine and Pathology

Volumn 19, Issue 4, 1998, Pages 362-367

  DiSiena, Michael R ^a   Intres, Richard ^a,b   Carter, Daniel J ^a,b  

^a BERKSHIRE MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Activated protein C; Factor V Leiden; Oral contraceptive; Pulmonary emboli; Venous thromboembolus

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; ASTHMA; AUTOPSY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CASE REPORT; FEMALE; GENE MAPPING; GENE MUTATION; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; LUNG EMBOLISM; ORAL CONTRACEPTION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

BIOLOGY; CASE STUDIES--WOMEN; CONTRACEPTION; CONTRACEPTIVE METHODS; DISEASES; EMBOLISM; FAMILY PLANNING; HEMATOLOGICAL EFFECTS--WOMEN; HEMIC SYSTEM; ORAL CONTRACEPTIVES; PHYSIOLOGY; PULMONARY EMBOLISM--WOMEN; RESEARCH METHODOLOGY; RESEARCH REPORT; STUDIES; THROMBOEMBOLISM--WOMEN; VASCULAR DISEASES; WOMEN;

ADULT; ASTHMA; BLOOD COAGULATION DISORDERS; CONTRACEPTIVES, ORAL; FACTOR V; FATAL OUTCOME; FEMALE; HUMANS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PULMONARY EMBOLISM;

EID: 0032435656     PISSN: 01957910     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000433-199812000-00013     Document Type: Article

References (26)

1. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
2. Dahlback B, Hillebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396-1400.
3. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
4. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994;343:1535-6.
5. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-8.
6. Heeb MJ, Koijima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995;85:3405-11.
7. Bauer KA. Hypercoagulability - a new cofactor in the protein C anticoagulant pathway. N Engl J Med 1994;330: 566-7.
8. Bauer KA. The hypercoagulable state. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams hematology, 5th ed. New York: McGraw-Hill, 1995:1531-50.
9. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-22.
10. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342: 1503-6.
11. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993;82:1989-93.
12. Jandl JH. Blood textbook of hematology, 2nd ed. Boston: Little, Brown and Co., 1996:1415-60.
13. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995;332: 912-7.
14. Simioni P, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-403.
15. Ridker PM, Glynn RJ, Miletich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden. Ann Intern Med 1997; 126:528-31.
16. Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992;31: 3777-85.
17. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp K, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997; 177:887-91.
18. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344: 1453-7.
19. Middeldorp S, Henkens CMA, Koopman MMW, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998;128:15-20.
20. van der Meer FJ, Rosendal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993;153: 1557-62.
21. Rosendaal FR, Bertina RM, Reitsma PH. Evaluation of activated protein C resistance in stored plasma. Lancet 1994;343:1289-90.
22. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 1997;277:1305-7.
23. Perry DJ, Pasi KJ. Resistance to activated protein C and factor V Leiden. Q J Med 1997;90:379-85.
24. Swibertus RP, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
25. Chan WP, Lee CK, Lam Kwong CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998;91:1135-9.
26. Williamsom D, Brown K, Luddington R, et al. Factor V Cambridge: a new mutation (Arg306-Thr) associated with resistance to activated protein C. Blood 1998;91:1140-4.